A study initiated by a University of Arizona Comprehensive Cancer Center physician-scientist defined for the first time how loss of the Y chromosome in male immune cells negatively affects immune system function, which may explain why loss of Y is asso…
Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously treated gastric or gastro-esophageal junction cancer, according to a multicenter randomized trial led by Peking University Cancer Ho…
A study conducted by researchers at the Center for Cell-Based Therapy (CTC) highlights key proteins and signaling pathways involved in the efficacy of immunotherapy based on CAR-T cells (lymphocytes modified in the laboratory to fight cancer).
After FDA approval in late 2023, the non-invasive liver tumor treatment histotripsy has been used at University of Michigan Health since early 2024.
The Experimental Drug Development Center (EDDC), Singapore’s national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase I trial for EBC-129 at the 2025 Annual Meeting of the Ameri…
A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endomet…
Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI in collaboration with Inselspital—Bern University Hos…
Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival…
Although immunotherapy is among the most significant advances in cancer care, it is not effective in all patients. University of Helsinki researchers have provided new insights into why some breast cancer treatments may not be as effective for all pati…
A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.
